alpha1-adrenergic receptor subtypes in human peripheral blood lymphocytes.

We investigated the expression of alpha1-adrenergic receptor subtypes in intact human peripheral blood lymphocytes using reverse transcription-polymerase chain reaction (RT-PCR) and radioligand binding assay techniques combined with antibodies against the three subtypes of alpha1-adrenergic receptors (alpha1A, alpha1B, and alpha1D). RT-PCR amplified in peripheral blood lymphocytes a 348-bp alpha1A-adrenergic receptor fragment, a 689-bp alpha1B-adrenergic receptor fragment, and a 540-bp alpha1D-adrenergic receptor fragment. Radioligand binding assay with [3H]prazosin as radioligand revealed a high-affinity binding with a dissociation constant value of 0. 65+/-0.05 nmol/L and a maximum density of binding sites of 175. 3+/-20.5 fmol/10(6) cells. The pharmacological profile of [3H]prazosin binding to human peripheral blood lymphocytes was consistent with the labeling of alpha1-adrenergic receptors. Antibodies against alpha1A-, alpha1B-, and alpha1D-receptor subtypes decreased [3H]prazosin binding to a different extent. This indicates that human peripheral blood lymphocytes express the three alpha1-adrenergic receptor subtypes. Of the three different alpha1-adrenergic receptor subtypes, the alpha1B is the most represented and the alpha1D, the least. Future studies should clarify the functional relevance of alpha1-adrenergic receptors expressed by peripheral blood lymphocytes. The identification of these sites may represent a step for evaluating whether they represent a marker of alpha1-adrenergic receptors in cardiovascular disorders or for assessing responses to drug treatment on these receptors.

[1]  P. Sleight The sympathetic nervous system in hypertension: differing effects of drug treatment. , 1998, European heart journal.

[2]  R. Jacobs,et al.  Expression and in-vivo modulation of α- and β-adrenoceptors on human natural killer (CD16+) cells , 1997, Journal of Neuroimmunology.

[3]  R. Schmieder,et al.  Overview of α1-Adrenoceptor Antagonism and Recent Advances in Hypertensive Therapy , 1996 .

[4]  C. Melchiorre,et al.  Synthesis, absolute configuration, and biological profile of the enantiomers of trans-[2-(2,6-dimethoxyphenoxy)ethyl] [(3-p-tolyl-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amine (mephendioxan), a potent competitive alpha 1A-adrenoreceptor antagonist. , 1996, Journal of medicinal chemistry.

[5]  R. Graham,et al.  alpha 1-adrenergic receptor subtypes. Molecular structure, function, and signaling. , 1996, Circulation research.

[6]  R. Villalobos-Molina,et al.  α1-Adrenoceptors mediating contraction in arteries of normotensive and spontaneously hypertensive rats are of the α1D or α1A subtypes , 1996 .

[7]  J. Hieble,et al.  α‐ and β‐Adrenoceptors: From the Gene to the Clinic. Part 2. Structure‐Activity Relationships and Therapeutic Applications , 1996 .

[8]  J. Hieble,et al.  Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. , 1995, Journal of medicinal chemistry.

[9]  M. S. Smith,et al.  Identification of the mRNA for the novel alpha 1D-adrenoceptor and two other alpha 1-adrenoceptors in vascular smooth muscle. , 1994, Molecular pharmacology.

[10]  P. Molinoff,et al.  International Union of Pharmacology nomenclature of adrenoceptors. , 1994, Pharmacological reviews.

[11]  B. Allolio,et al.  Reduced lymphocyte β2‐adrenoceptor density and impaired diastolic left ventricular function in patients with glucocorticoid deficiency , 1994, Clinical endocrinology.

[12]  C. Mathias,et al.  Expression of beta-adrenoceptors on circulating mononuclear cells in hypertensives and normotensives before and after reduction of central sympathetic outflow by clonidine. , 1994, Blood pressure.

[13]  G. Maestroni,et al.  Noradrenergic modulation of lymphohematopoiesis. , 1994, International journal of immunopharmacology.

[14]  M. Michel,et al.  Radioligand binding studies of α1‐adrenoceptor subtypes in rat heart , 1994 .

[15]  E. Borda,et al.  Active alpha2 and beta adrenoceptors in lymphocytes from patients with chronic lymphocytic leukemia , 1991, International journal of cancer.

[16]  M. Caron,et al.  Molecular cloning and expression of the cDNA for the alpha 1A-adrenergic receptor. The gene for which is located on human chromosome 5. , 1991, The Journal of biological chemistry.

[17]  Debra,et al.  Molecular cloning and expression of the cDNA for a novel alpha 1-adrenergic receptor subtype. , 1990, The Journal of biological chemistry.

[18]  M. Caron,et al.  Molecular cloning and expression of the cDNA for the hamster alpha 1-adrenergic receptor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[19]  A. Daul,et al.  Alpha- and beta-adrenoceptors in circulating blood cells of essential hypertensive patients: increased receptor density and responsiveness. , 1985, Clinical and experimental hypertension. Part A, Theory and practice.

[20]  T. Casale,et al.  Demonstration that circulating human blood cells have no detectable alpha 1-adrenergic receptors by radioligand binding analysis. , 1984, The Journal of allergy and clinical immunology.

[21]  S. Titinchi,et al.  Alpha 2-adrenoceptors in human lymphocytes: direct characterisation by [3H]yohimbine binding. , 1984, Biochemical and biophysical research communications.

[22]  P. Molenaar,et al.  Analysis of dose-response curves and calculation of agonist dissociation constants using a weighted nonlinear curve fitting program. , 1983, Journal of pharmacological methods.

[23]  G. Delespesse,et al.  Distribution of beta-adrenergic receptors on human lymphocyte subpopulations. , 1979, Clinical and experimental immunology.

[24]  R. Schmieder,et al.  Overview of alpha 1-adrenoceptor antagonism and recent advances in hypertensive therapy. , 1996, American journal of hypertension.

[25]  M. Michel,et al.  Radioligand binding studies of alpha 1-adrenoceptor subtypes in rat heart. , 1994, British journal of pharmacology.

[26]  R. Lefkowitz,et al.  Beta adrenergic receptors in lymphocyte subpopulations. , 1980, The Journal of allergy and clinical immunology.